Tag: Aortic stenosis

Over 5 million people in the U.S. are diagnosed with heart valve disease each year. While medications cannot cure the underlying valve issue, understanding what is the medical treatment for heart valves is key to managing symptoms and improving quality of life.

In patients with severe aortic stenosis, the heart’s ability to pump blood is already significantly compromised. This fixed obstruction to left ventricular outflow is the primary reason **why is hydralazine contraindicated in aortic stenosis** due to the severe hemodynamic consequences of its vasodilatory action.

Affecting up to 9.8% of individuals aged 80-89, aortic stenosis is a serious valve condition [1.5.1]. Understanding **why are CCBs contraindicated in aortic stenosis** is crucial, as these drugs can cause dangerous drops in blood pressure and cardiac output [1.2.1].

The prevalence of aortic stenosis in individuals over 75 is approximately 12.4%, with 3.4% having a severe form that may require Transcatheter Aortic Valve Implantation (TAVI) [1.6.1]. Proper medication management is crucial, so understanding what medications should be stopped before TAVI is a key safety measure.

Following transcatheter aortic valve replacement (TAVR), balancing the risk of ischemic events with the risk of major bleeding is crucial, with recent meta-analyses showing that dual antiplatelet therapy (DAPT) is associated with an increased risk of bleeding compared with single antiplatelet therapy (SAPT). The optimal duration of antiplatelet therapy after TAVR has shifted significantly, moving away from prolonged dual-therapy regimens for most patients.

According to official FDA labeling, advanced aortic stenosis is a specific contraindication for the use of nicardipine. This critical prohibition stems from the fundamental physiological mismatch between the heart's pathology and the medication's primary mechanism of action, which can lead to severe and dangerous hemodynamic consequences for the patient.

Aortic stenosis (AS) affects up to 10% of people over 80 and is the most common adult heart valve condition in the Western world. For this condition, there is no single "drug of choice," as medication cannot reverse or stop the progression of the narrowed heart valve. Instead, drugs are used to manage related symptoms and comorbidities while preparing for definitive, interventional treatment.

Despite initial promise based on the similarities between calcific aortic stenosis and atherosclerosis, major randomized controlled trials have conclusively demonstrated that statins do not prevent aortic stenosis or slow its progression. This surprising finding has reshaped the understanding of the disease's progression and the role of lipid-lowering therapy in managing it.

Over 1.5 million Americans are affected by symptomatic spinal stenosis, but for the condition as a whole, there is no singular **what is the drug of choice for stenosis?**. The answer is complex because "stenosis" refers to any abnormal narrowing of a vessel or opening, meaning medication depends entirely on the location and cause of the narrowing.